Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Metastatic
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
Is there a role of olaparib in light of TBCRC 048 data showing response in somatic mutations?
Related Questions
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?
What are your top takeaways in Breast Cancer from ASTRO 2024?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?